—A pilot study of 9 patients with aplastic anemia and paroxysmal nocturnal hemoglobinuria asked them to track their symptoms over a 6-month period. The results were encouraging, suggesting a place for ...

In this interview, we spoke with Gloria Gerber, MD, a hematologist and assistant professor of medicine at Johns Hopkins University, about the evolution of treatment for paroxysmal nocturnal ...

—Most patients with paroxysmal nocturnal hemoglobinuria who have been treated with at least 1 year of C5 inhibitor therapy still have hemoglobin levels below 12.0 g/dL. Continued fatigue and other ...

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disease that can cause fatigue due to anemia. PNH is closely associated with fatigue due to a loss of red blood cells, leading to anemia. This ...

Iptacopan demonstrated significant hemoglobin improvements in PNH patients transitioning from anti-C5 therapies, validating its efficacy as an oral monotherapy. The safety profile of iptacopan was ...

AJMC ®: Paroxysmal nocturnal hemoglobinuria (PNH) is 1 of several complement-driven diseases. Can you describe its clinical presentation? DE CASTRO: PNH presents heterogeneously. One of the 3 ...

Diagnosed at a young age with a rare and potentially life-threatening disease, one man learned the power of taking control. When South Carolinian Roger was diagnosed with paroxysmal nocturnal ...

(RTTNews) - Swiss drug major Novartis AG (NVS) announced Friday that Fabhalta (iptacopan) has received a positive opinion from the Committee for Medicinal Products for Human Use or CHMP of the ...